Market research
MYNZ Mainz Biomed BV
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 11M
- P/E ratio
- Not available
- Analyst target
- 14
- Dividend yield
- Not available
- Beta
- 0.32
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- NL0015000LC2
- Market cap
- 11M
- P/E ratio
- Not available
- Analyst target
- 14
- Dividend yield
- Not available
- Beta
- 0.32
About
About Mainz Biomed BV
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product. Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the MYNZ discussion.
No comments yet
Start a focused discussion about MYNZ.